Evidence-Based Reviews

Preventing drinking relapse in patients with alcoholic liver disease

Current Psychiatry. 2015 December;14(12):22-28,30-32

References

1. Gache P, Hadengue A. Baclofen improves abstinence in alcoholic cirrhosis: still better to come? J Hepatol. 2008;49(6):1083-1085.
2. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223-2233.
3. Singal AK, Kamath PS, Gores GJ, et al. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol. 2014;12(4):555-564; quiz e31-32.
4. Becker U, Deis A, Sørensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025-1029.
5. Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol. 2012;56(suppl 1):S39-S45.
6. Mann K, Lemenager T, Hoffmann S, et al; PREDICT Study Team. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013;18(6):937-946.
7. Anton RF, O’Malley SS, Ciraulo DA, et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017.
8. Kranzler HR, Rosenthal RN. Dual diagnosis: alcoholism and co-morbid psychiatric disorders. Am J Addict. 2003;12(suppl 1):S26-S40.
9. Book SW, Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs. 2005;14(4):371-376.
10. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691-1700.
11. Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481-1488.
12. Krystal JH, Cramer JA, Krol WF, et al; Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739.
13. Petrakis IL, Poling J, Levinson C, et al; VA New England VISN I MIRECC Study Group. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57(10):1128-1137.
14. Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293.
15. Pettinati HM, O’Brien CP, Rabinowitz AR, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006;26(6):610-625.
16. Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709-717.
17. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005(1):CD001867.
18. Naltrexone. 2014. http://www.micromedexsolutions.com. Accessed January 31, 2015.
19. Soyka M, Chick J. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. Am J Addict. 2003;12(suppl 1):S69-S80.
20. Turncliff RZ, Dunbar JL, Dong Q, et al. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45(11):1259-1267.
21. United States National Library of Medicine. Naltrexone. http://livertox.nlm.nih.gov/Naltrexone.htm. Updated September 30, 2015. Accessed November 10, 2015.
22. Terg R, Coronel E, Sordá J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002;37(6):717-722.
23. Skinner MD, Lahmek P, Pham H, et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis [published online February 10, 2014]. PLoS One. 2014;9(2):e87366. doi: 10.1371/journal.pone.0087366.
24. Disulfiram. 2014. http://www.micromedexsolutions.com. Accessed January 31, 2015.
25. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol. 2006;44(4):791-797.
26. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999;20(5):427-435.
27. Campral [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2012.
28. Brower KJ, Myra Kim H, Strobbe S, et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429-1438.
29. Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70-77.
30. Neurontin [package insert]. New York, NY: Pfizer; 2015.
31. Johnson BA, Ait-Daoud N, Akhtar FZ, et al. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61(9):905-912.
32. Paparrigopoulos T, Tzavellas E, Karaiskos D, et al. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.
33. Rubio G, Ponce G, Jiménez-Arriero MA, et al. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004;37(1):37-40.
34. Topamax [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2009.
35. De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat. 2008;34(4):460-463.
36. Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013;133(1):94-99.
37. Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46(3):312-317.
38. Balcofen [package insert]. Concord, NC: McKesson Packing Services; 2013.
39. United States National Library of Medicine. Baclofen. 2015. http://livertox.nlm.nih.gov/Baclofen.htm. Accessed November 7, 2015.
40. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915-1922.
41. Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37(4):561-564.
42. Franchitto N, Pelissier F, Lauque D, et al. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 2014;49(1):79-83.
43. Brennan JL, Leung JG, Gagliardi JP, et al. Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clin Pharmacol. 2013;5:99-107.
44. Rösner S, Leucht S, Lehert P, et al. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11-23.
45. Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention, and treatment. Addict Behav. 2002;27(6):867-886.
46. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105(1):14-32; quiz 33.

Preventing drinking relapse in patients with alcoholic liver disease

References

Pages

Recommended Reading